The Use of Methylphenidate During Inpatient Rehabilitation After Pediatric Traumatic Brain Injury: Population Characteristics and Prescribing Patterns.
Eric Caliendo, Ryan Lowder, Matthew J McLaughlin and 9 others
PMID 38709832WHAT IT FOUND
Prescribing methylphenidate in pediatric TBI rehab is highly variable, with an 18-fold difference in starting doses.
Patients receiving it were generally older and had more severe injuries. This describes current practice patterns rather than proving the medication improves recovery.
Key findings
01Methylphenidate was prescribed to 62 of 234 patients, with those receiving it being older and having longer acute care stays before rehabilitation admission.
02Weight-based dosing varied drastically, with an 18-fold difference in the lowest recorded doses and a median maximum dose of 0.41 mg/kg/day.
03Side effects were reported in 5 patients (8%), but no serious adverse events occurred, and the study did not evaluate cognitive changes resulting from the medication.
STILL TO COME
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The retrospective design means the study cannot determine if MPH caused any clinical improvement, only that it was prescribed. The study did not measure cognitive or behavioral outcomes before and after MPH administration, so it cannot assess efficacy. Adverse event data relied on free-text clinical notes without standardized search criteria, which may have led to underreporting of side effects. The sample size was limited, and the study did not account for socioeconomic factors that might influence length of stay or treatment decisions. Cognitive state assessments varied across sites, and there were no reliable standardized measures for tracking recovery in very young children.
Declared interests
The authors declared no conflicts of interest.
The easy way to misread this
Do not interpret the lack of serious adverse events as evidence that methylphenidate is safe or effective for pediatric TBI recovery. The study did not measure functional outcomes, and the low reported side effect rate may be due to inconsistent documentation in medical records rather than actual tolerability.